Multivariate regression analysis of structural MRI connectivity matrices in Alzheimer’s disease

Alzheimer's disease (AD) is the most common form of dementia among older people and increasing longevity ensures its prevalence will rise even further. Whether AD originates by disconnecting a localized brain area and propagates to the rest of the brain across disease-severity progression is a...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 12; no. 11; p. e0187281
Main Authors Rasero, Javier, Amoroso, Nicola, La Rocca, Marianna, Tangaro, Sabina, Bellotti, Roberto, Stramaglia, Sebastiano
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 14.11.2017
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Alzheimer's disease (AD) is the most common form of dementia among older people and increasing longevity ensures its prevalence will rise even further. Whether AD originates by disconnecting a localized brain area and propagates to the rest of the brain across disease-severity progression is a question with an unknown answer. An important related challenge is to predict whether a given subject, with a mild cognitive impairment (MCI), will convert or not to AD. Here, our aim is to characterize the structural connectivity pattern of MCI and AD subjects using the multivariate distance matrix regression (MDMR) analysis, and to compare it to those of healthy subjects. MDMR is a technique developed in genomics that has been recently applied to functional brain network data, and here applied to identify brain nodes with different connectivity patterns, in controls and patients, because of brain atrophy. We address this issue at the macroscale by looking to differences in individual structural MRI brain networks, obtained from MR images according to a recently proposed definition of connectivity which measures the image similarity between patches at different locations in the brain. In particular, using data from ADNI, we selected four groups of subjects (all of them matched by age and sex): HC (healthy control participants), ncMCI (mild cognitive impairment not converting to AD), cMCI (mild cognitive impairment converting to AD) and AD. Next, we built structural MRI brain networks and performed group comparison for all the pairs of groups. Our results were three-fold: (i) considering the comparison of HC with the three other groups, the number of significant brain regions was 4 for ncMCI, 290 for cMCI and 74 for AD, out of a total of 549 regions; hence, in terms of the structural MRI connectivity here adopted, cMCI subjects have the maximal altered pattern w.r.t. healthy conditions. (ii) Eight and seven nodes were significant for the comparisons AD-ncMCI and AD-cMCI, respectively; six nodes, among them, were significant in both comparisons and these nodes form a connected brain region (corresponding to hippocampus, amygdala, Parahippocampal Gyrus, Planum Polare, Frontal Orbital Cortex, Temporal Pole and subcallosal cortex) showing reduced strength of connectivity in the MCI stages; (iii) The connectivity maps of cMCI and ncMCI subjects significantly differ from the connectome of healthy subjects in three regions all corresponding to Frontal Orbital Cortex.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Membership of the Alzheimer’s Disease Neuroimaging Initiative is provided in the Acknowledgments.
Competing Interests: ADNI is in part funded by generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The support to ADNI from these companies does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0187281